FDA Expands Jemperli (dostarlimab-gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
FDA approves Jemperli plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, including those with MMRp/MSS tumors, based on RUBY phase III trial results showing significant OS benefit.
Highlighted Terms
Related News
FDA Expands Jemperli (dostarlimab-gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
FDA approves Jemperli plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, including those with MMRp/MSS tumors, based on RUBY phase III trial results showing significant OS benefit.